SIGN IN YOUR ACCOUNT TO HAVE ACCESS TO DIFFERENT FEATURES

FORGOT YOUR PASSWORD?

FORGOT YOUR DETAILS?

AAH, WAIT, I REMEMBER NOW!
+1 786 238 2170

Global Stem Cells GroupGlobal Stem Cells Group

  • Home
  • Our Story
  • Speakers
  • Investors
  • Companies
  • Press Releases
  • Blog
CONTACT
  • Home
  • Press Releases
  • Global Stem Cells Group Set to Conduct Clinical Trials in Miami
May 21, 2025

Global Stem Cells Group Set to Conduct Clinical Trials in Miami

Thursday, September 26, 2019 / Published in Press Releases

Global Stem Cells Group Set to Conduct Clinical Trials in Miami

MIAMI LAKES, Florida—The Global Stem Cells Group (GSCG), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine, announced its participation in a new clinical trial in Miami. The trial is sponsored by InGeneron, Inc. and will provide researchers the opportunity to compare two treatment options in patients with partial-thickness rotator cuff tears (PTRCTs). Patient groups will be injected either with a single injection of adipose-derived regenerative cells (ADRCs) or a single corticosteroid injection to examine the efficacy of both treatment protocols.

The study is a prospective, double-blinded, randomized, active-controlled, multi-site, pivotal safety and superior effectiveness study in patients with symptomatic partial-thickness rotator cuff tears. Researchers will compare a single ADRC injection generated with the Transpose® RT system into the supraspinatus tendon and surrounding area to standard-of-care (SOC) corticosteroid injection into the subacromial bursa.

Up to 20 U.S. centers will be initiated to enroll in the study. Two hundred and forty six subjects will be assigned to two randomization arms: an adipose-derived regenerative cell (ADRC) injection arm (ADRC treatment arm) and the SOC corticosteroid injection arm (active control arm). All subjects will be randomly assigned to the ADRC treatment or active control arms in a 2:1 ratio.

The GSCG clinical trial is registered with the US Food and Drug Administration (FDA) and will adhere to all FDA safety protocols. The GSCG will help recruit patients for the study. The goal of the trial is to demonstrate the safety and efficacy of stem cells treatments in helping to treat patients suffering from degenerative diseases and injuries such as PTRCTs.

“The Global Stem Cells Group is committed to helping people across the globe find relief from debilitating diseases and is pleased to serve as a leader in cutting-edge research in the stem cells field,” said Benito Novas, CEO of the Global Stem Cells Group. “This clinical trial will hopefully help us achieve these goals by demonstrating the safety and efficacy of regenerative medicine treatments to physicians, patients, and regulatory bodies so that more patients are able to have access to these treatment protocols and find relief.”

To learn more about the clinical trial, visit https://clinicaltrials.gov/ct2/show/NCT03752827. To learn more about the Global Stem Cells Group and its latest efforts, visit http://www.stemcellsgroup.com/. 

Tagged under: Global and LaHo, global stem cells group, Global Stem Cells Group network, Good Manufacturing Practice, ISSCA, Laho, Lans Holdings

What you can read next

Stem Cell Training Inc. Announces Alliance with Far Eastern University to Advance in-Office Stem Cell Procedures
Stem Cell Training, Inc. Announces Joint Venture with The Research Center in Tissue Engineering and Cellular Therapy at Maimonides University
Global Stem Cells Group, Inc. Announces Plans to Attend 21st Annual World Congress on Anti-Aging, Regenerative and Aesthetic Medicine in Las Vegas, Dec. 15, 2013

Leave a Reply

Your email address will not be published. Required fields are marked *

Send Us a Message

Contact Home GSCG website

Name(Required)
Email(Required)
Please let us know what's on your mind. Have a question for us? Ask away.
  • Home
  • Our Story
  • Speakers
  • Investors
  • Companies
  • Testimonials
  • Press Releases
  • Blog

Copyright © 2024 Stem Cells Group | All Rights Reserved

CONTACT US

Datran Center 9100 S Dadeland Boulevard, Suite 1500. Miami Fl. 33156 United States

305-560-5337

info@stemcellsgroup.com

STAY CONNECTED

Get the latest news, updates, and promotions. Follow us on our social networks.

Certification issued by ISSCA

  • Home
  • Our Story
  • Speakers
  • Investors
  • Companies
  • Testimonials
  • Press Releases
  • Blog

Copyright © 2024 Stem Cells Group | All Rights Reserved

CONTACT US

Datran Center 9100 S Dadeland Boulevard, Suite 1500. Miami Fl. 33156 United States

305-560-5337

info@stemcellsgroup.com

STAY CONNECTED

Get the latest news, updates, and promotions. Follow us on our social networks.

Certification issued by ISSCA

TOP